Beijing Arion Cancer Center
Beijing Arion Cancer Center — Beijing
Hospital Profile
Beijing Meizhong Airui Cancer Hospital is a tertiary private specialized cancer hospital approved by the Beijing Municipal Health Commission in January 2021, located in Daxing District, Beijing (Mingchun East Road / Youlong Road, Mingchunyuan). The hospital covers an area of 24,000 to 32,000 square meters, with planned/approved 400 beds, and was officially included as a designated medical institution for Beijing medical insurance on June 1, 2022 (fully supporting medical insurance consultations). The hospital is positioned as 'advanced diagnostic and treatment technology, affordable medical insurance prices, public hospital doctor team, and personalized humanistic services.' It is a comprehensive cancer diagnosis and treatment platform for the public, with the core treatment philosophy being a full-process, real-time tertiary MDT (multidisciplinary treatment) model.
Medical Milestones
• January 2021: Approved and established for operation by the Beijing Municipal Health Commission. • June 1, 2022: Officially included as a designated medical institution under Beijing's medical insurance. • April 15, 2026: Hosted "Complex Tumors: Not Just Treatment, But Also Planning — Patient Value Roundtable Forum" and launched the "2,000 Case Tumor MDT Careplan Full-Process Management Clinical Research Project."
Key Capabilities & Patient Care
• Core Competencies: Focused on precise treatment and comprehensive management of various tumors, especially complex and difficult cases such as advanced, recurrent metastatic, multiple primary, and rare tumors; building a specialized diagnosis and treatment system centered on MDT (multidisciplinary team) care; established multiple centers including those for lung cancer, breast cancer, gynecologic tumors, gastrointestinal tumors, neurological tumors, hepatobiliary tumors, urinary tumors, hematologic/lymphoid malignancies, head and neck/thyroid tumors, oncology rehabilitation, cell therapy, endoscopy, precision health medicine, and cancer prevention screening; constructing a full-chain closed-loop diagnosis and treatment process of 'diagnosis—decision—treatment—assessment—adjustment—rehabilitation—follow-up' along with a 'Careplan (full-course dynamic planning)' total management system. • Patient Care: Possesses an oncology doctor team and case managers from Beijing public hospitals; established a full-process service mechanism integrating digital follow-up, interdisciplinary collaboration, and patient community engagement; emphasizes psychological counseling, nutritional support, and pain management for patients, providing personalized and humanistic services along with full-course dynamic optimization of diagnosis and treatment.
Advanced Technology
Equipped with advanced domestic and international examination, diagnostic, and treatment equipment, including PET-CT, MRI, CT, digital subtraction angiography (DSA), mammography, breast ABUS, endoscopic ultrasound, linear accelerator, brachytherapy machine, etc.; has radiology imaging center/department, radiotherapy center/department, interventional center/department, pathology center/department, ultrasound department, laboratory department, and other medical technology departments; uses next-generation sequencing technology (covering more than 18,000 genes and 763 core tumor genes, fully scanning all exonic regions) for high-precision genetic testing. Data statistics: • Bed capacity: Planned/approved 400 beds; covering an area of 24,000–32,000㎡ • Number of departments: Includes centers for lung cancer, breast cancer, gynecological tumors, gastrointestinal tumors, neuro-oncology, hepatobiliary tumors, urological tumors, hematologic/lymphoma, head and neck/thyroid tumors, tumor rehabilitation, cell therapy, endoscopy, precision health medicine, cancer prevention and screening, plus medical technology departments such as radiology imaging, radiotherapy, interventional, pathology, ultrasound, and laboratory • Number of full-time physicians: Not disclosed • Number of multi-site practitioners/specially appointed experts: Total number not disclosed; verified multi-site practitioners: Li Jinfeng (Chief Physician, Peking University Cancer Hospital), Xi Zhijun (Chief Physician, Peking University First Hospital), etc. (2026) • Annual outpatient volume: Annual outpatient volume not disclosed • Surgical capability: Centered on MDT comprehensive diagnosis and treatment; equipment includes PET-CT, DSA, linear accelerator, brachytherapy machine, endoscopic ultrasound, etc.; high-precision genetic testing covers 18,000 genes/763 core tumor genes; surgical volume not disclosed • International certification and qualifications: Approved for establishment by Beijing Municipal Health Commission in 2021; included as a designated hospital for Beijing medical insurance in 2022; Grade III private oncology specialty hospital • International services: Not disclosed
International Patient Services
• Established a long-term partnership with UPMC (an academic medical center affiliated with the University of Pittsburgh School of Medicine). • By leveraging the policies of the new drug outpatient clinic and Boao Lecheng International Medical Tourism Pilot Zone, simultaneously introduce internationally advanced new drugs and diagnostic and treatment technologies, narrowing the gap between domestic and foreign oncology treatment technologies, and providing cutting-edge medical resource support for both international and local patients.